NoWay
It's time to play the game
Dovresti postarlo anche nel thread High Yield...
Obbligazioni in dollari Keep Calm And Invest Preferred Shares Usa (2 lettori)
Dovresti postarlo anche nel thread High Yield...
Fabrib
Forumer storico
TUSTIN, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced that four preclinical abstracts and one clinical abstract have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research (AACR), to be held April 1 - 5, 2017 in Washington, D.C.
Peregrine scientists and collaborators will present positive findings from multiple studies of the company's phosphatidylserine (PS)-targeting antibodies in combination with other anti-tumor agents, including results from two Memorial Sloan Kettering Cancer Center studies that evaluate the use of a bavituximab equivalent in combination with immune stimulating therapies.
Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting | 4-Traders
PHM) (NASDAQPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced that four preclinical abstracts and one clinical abstract have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research (AACR), to be held April 1 - 5, 2017 in Washington, D.C.Peregrine scientists and collaborators will present positive findings from multiple studies of the company's phosphatidylserine (PS)-targeting antibodies in combination with other anti-tumor agents, including results from two Memorial Sloan Kettering Cancer Center studies that evaluate the use of a bavituximab equivalent in combination with immune stimulating therapies.
Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting | 4-Traders
Joe Silver
Forumer storico
Tanto per suscitare la vostra invidia
devo confessare di avere preso Spark (purtroppo solo 200 azioni) subito dopo la segnalazione di Fabrib, che doverosamente ringrazio, a 24,95 
NoWay
It's time to play the game
Tanto per suscitare la vostra invidia
... scherzoooo... bravi voi e lesso io a cercare di prenderla più in basso...
bulogna
Forumer storico
Tanto per suscitare la vostra invidia
Peco
Forumer storico
captain sparrow
Forumer storico
una domanda. se io ho in pf le azioni alla data in cui vanno ex dividend, e le vendo dopo qualche giorno, il dividendo mi viene pagato, quando va in pagamento dopo diciamo 20/30 gg anche se le ho vendute? vi autorizzo a farvi una risata, ma sono un quasi vergine in fatto di preffered. ciao a tutti grazie
angy2008
Forumer storico
certo che te lo pagano, c'è gente che campa solo tradando le preferred tra le date pre e post record, non è il mio caso ma qualcuno c'è anche in questo forum, ciao